Four steps for Hong Kong to tackle fast-rising healthcare costs
Avoiding this crisis requires a transformation in cooperation between healthcare providers, insurers and health authorities, underpinned by technology integration across the whole system.
Ignoring the impact of Covid-19, healthcare costs rose by 23 per cent in the five years to 2023, with taxpayer-funded costs increasing from 50 per cent of the total to 52 per cent and out-of-pocket costs averaging 30 per cent of total spending for that period. Government healthcare spending grew by 28 per cent, and insurance funding has not reduced the burden on taxpayers and out-of-pocket costs.
Relative contributions to healthcare funding from private and employer-based insurance schemes have not grown meaningfully in the past five years, averaging 17 per cent of total spending. Health insurers are struggling with profitability because of inflation in medical costs, leading them to increase premiums. This constrains the take-up of private insurance, adding a new dimension to the sustainability problem.
Increasing healthcare costs can only be met through higher private insurance premiums, increased government expenditure and higher out-of-pocket spending. There is no magic fourth way to fund the system.
Advertisement
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
a day ago
- South China Morning Post
Are you developing Parkinson's disease? Earwax may show if you are at risk, study says
Chinese researchers investigating Parkinson's disease have made a curious discovery related to earwax that could improve the prospects of prevention and diagnosis. A team based at Zhejiang University in Guangzhou has found that earwax tests could help with the early detection of the debilitating disease, which is difficult to treat and has no cure. Earwax from people with Parkinson's disease were significantly different than the earwax from people without the disease,' according to the American Chemical Society, which published the team's findings. The researchers were following up on previous work showing that Parkinson's sufferers' sebum – an oily substance secreted through the skin – has a different odour than that of people without the disease. Since earwax is largely made up of sebum, the team realised it would make for a potentially telling research target. Earwax is a naturally occurring substance produced in the ear canal to protect and clean the ear. Photo: dpa After screening samples taken from more than 200 people, the team found alterations in four volatile organic compounds – organic chemicals that easily evaporate into the air – in Parkinson's patients' earwax. These changes do not appear in the compounds in the sebum of those who do not have Parkinson's.
South China Morning Post
2 days ago
- South China Morning Post
New drug approval system takes Hong Kong closer to biomedical hub goal
Hong Kong has good reason to aspire to its own internationally recognised regime for approving pharmaceutical drugs . Intense global demand for Covid-19 vaccines remains fresh in the memory. The city also happens to rank No 2, behind only New York, as a market for biomedical and pharmaceutical companies to raise capital. To realise this goal, developing independent clinical trial capacity and a regulatory framework comparable with the US Food and Drug Administration would go a long way. It would also raise Hong Kong's standing as a medical innovation hub. Advertisement It is therefore good to hear from health authorities that the city will begin reviewing and approving drugs independently in phases from 2026. A new regulatory system is set to begin operating by the end of next year, with more new medications expected to hit the local market before long. To clear the way, the Department of Health has unveiled a plan to set up a centre for the regulation of medical products, with the aim of becoming a recognised international drug regulation authority. This is the final link in a road map for the development of primary drug evaluation, an approach foreshadowed in Chief Executive John Lee Ka-chiu's 2023 policy address. This will speed up product reviews. Primary evaluation means approving drugs based on their clinical trial data, without relying on registration approval from other regulatory authorities. A preparatory office for the centre was set up in June last year to study and plan for a drug regulatory regime. The department said primary evaluation was expected to be implemented gradually over five years. To that end, Hong Kong recently opened its first clinical trial institute , located in a cross-border tech zone. The development of Hong Kong as a biomedical hub not only means business opportunities for the city, but resonates with vast market potential on the mainland, where people cannot always afford new drugs approved in the US. As a rapidly ageing society, Hong Kong has a multipronged interest in recognition as an Asian pharmaceutical and biomedical hub with big potential for healthcare shaped by biotech and bioscience. Advertisement
South China Morning Post
6 days ago
- South China Morning Post
Hong Kong woman opens up about life after moment her heart stopped beating
More than a decade ago, Hongkonger Olivia Cheung Lok-man's heart stopped beating for 63 minutes. She was a 19-year-old student at the time and had suffered a fulminant myocarditis attack, a rare and severe illness that can cause heart failure. Cheung, now a 30-year-old art teacher, has since developed the ability to cope with the uncertainties surrounding her condition, thanks to the special care of the medical team at Queen Mary Hospital's intensive care unit (ICU). 'I have experienced [near death], I don't think there's anything [my family and I] can't deal with,' she said. Cheung and her doctor spoke to the media on Monday as part of the hospital's work with the Shaw Foundation to offer in-person and online activities to educate the public about intensive care treatments and patients' experiences. Last year, lawmakers passed a legislative amendment that allows terminally ill patients to reject certain treatments, such as undergoing cardiopulmonary resuscitation (CPR), as the end of their life nears.
